英矽智能口服抗新冠3CL蛋白酶抑制剂临床试验申请获批 (IMAGE)

InSilico Medicine

英矽智能口服抗新冠3CL蛋白酶抑制剂临床试验申请获批

Caption

公司自主研发的抗新冠病毒口服创新药ISM3312已获得中国国家药监局的临床试验许可，即将进入临床试验阶段。

Credit

英矽智能

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.